Skip to main content

Table 2 The associated factors for HBeAg seroclearance in the univariate and multivariate analyses

From: Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study

 

Univariate

Multivariate

Factors

HR (95% CI)

p

HR (95% CI)

p

Gender (M vs F)

0.717 (0.482–1.064)

0.099

0.667 (0.404–1.099)

0.112

Antiviral treatment

 LAM

reference

 

reference

 

 ETV

1.602 (1.000–2.568)

0.050

1.182 (0.660–2.118)

0.573

 LdT

1.841 (1.098–3.087)

0.021

2.548 (1.338–4.853)

0.004

qHBsAg, log IU/mL

0.756 (0.579–0.999)

0.040

0.755 (0.515–1.107)

0.150

HBV DNA, log IU/mL

0.809 (0.686–0.955)

0.012

0.729 (0.546–0.972)

0.031

HS

0.851 (0.584–1.238)

0.399

0.680 (0.410–1.130)

0.137

  1. Variables with p < 0.1 in univariate analysis were analyzed in multivariate analysis
  2. HR Hazard ratio; CI Confidence interval; qHBsAg Quantitative HBsAg; LAM lamivudine; LdT Telbivudine; ETV Entecavir; HS Hepatic steatosis